Back to Rankings

AVIR

AteaD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The post-earnings company update kept the core thesis intact: C-BEYOND remains on track for mid-2026 topline, C-FORWARD is still progressing toward year-end 2026 data, and cash of $256.0 million supports operations through 2027, which gives AVIR time to reach its main HCV inflection points without an immediate financing need [#8-K-2026-05-12] [#10-Q-2026-05-12].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.4.
What can break
C-BEYOND is the dominant near-term value driver, so a weak or delayed mid-2026 topline readout would likely overwhelm the cash-backed valuation.
Momentum
12
Value
41
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $8.50 · Bear $2.20
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $6.00
Why
Momentum12 · Δ7d -3.6
Value41 · Δ7d +0.1
Sentiment67 · Δ7d +4.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
12
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.6
Δ21d
-55.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
67
33% active weight
Current posture
7d trendImproving
Δ7d
+4.4
Δ21d
+13.1
Why this grade

Composite grade D. Momentum 12.5 / Value 41.1 / Sentiment 67.0

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$350.52M
Beta
0.23
Shares Out
78.13M
P/E (TTM) · Derived
-2.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.78
Rev YoY
-
EPS YoY
-44.2%
Gross Margin
-
Op Margin
-
Net Debt
-$454.72M
Current Ratio
16.66
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology